What question did this study set out to answer?

The aim is to evaluate the effectiveness of an all-oral combination of acalabrutinib and venetoclax in improving outcomes for adults with chronic or small lymphocytic leukemia.

June 4, 2026

All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL

Key Points

The aim is to evaluate the effectiveness of an all-oral combination of acalabrutinib and venetoclax in improving outcomes for adults with chronic or small lymphocytic leukemia.
Phase 3 AMPLIFY trial conducted comparing acalabrutinib plus venetoclax to standard chemoimmunotherapy for adults with CLL or SLL.
Assessment of progression-free survival as primary endpoint.
Significantly improved progression-free survival observed in the acalabrutinib plus venetoclax group compared to standard chemoimmunotherapy.
Detailed metrics on event rates and statistical significance not provided in the summary.

Abstract

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, phase 3 AMPLIFY trial results show significantly improved progression‐free survival in comparison with standard chemoimmunotherapy for adults with chronic or small lymphocytic leukemia. In addition, a study adds new evidence on use of salvage focal therapy for radio‐recurrent prostate cancer, and stereotactic radiation is linked to fewer symptoms in patients with 5–20 brain metastases.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Leah Lawrence

Journals

Cancer

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

All‐oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study